Brief: Arch Biopartners Expands Main Goal Of Phase II Trial For Lead Drug LSALT Peptide In Patients With COVID-19
19/05/2020 22:49
May 19 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS EXPANDS THE PRIMARY ENDPOINT OF ITS PHASE
II
TRIAL TO INCLUDE PREVENTION OF MULTIPLE ORGAN INJURIES IN
PATIENTS WITH COVID-19
* ARCH BIOPARTNERS - PHASE II TRIAL EXPECTED TO COMMENCE IN
SUMMER
OF 2020
* ARCH BIOPARTNERS INC - PRIMARY ENDPOINT OF PHASE II TRIAL
NOW
INCLUDES ACUTE KIDNEY INJURY , CARDIOMYOPATHY, AS COMPONENTS, IN
COVID-19 PATIENTS
* ARCH - PRIMARY ENDPOINT OF PHASE II TRIAL INCLUDES ACUTE
LIVER
INJURY, COAGULOPATHY, ALL-CAUSE MORTALITY, AS COMPONENTS, IN
COVID-19 PATIENTS
Source text for Eikon: ID:nGNXgwzL8
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide